Everstar Asset Management LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• Everstar Asset Management LLC increased its stake in GSK PLC Sponsored ADR by 230.3% in the 1st quarter, now holding 26,300 shares valued at approximately $1,019,000.
• GSK recently reported earnings of $1.23 per share, surpassing analyst expectations, with revenue of $10.64 billion for the quarter.
• The company has declared a quarterly dividend of $0.4206 per share, representing a yield of 4.2%, with a dividend payout ratio of 77.78%.

Everstar Asset Management LLC raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 230.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,300 shares of the pharmaceutical company's stock after purchasing an additional 18,337 shares during the period. Everstar Asset Management LLC's holdings in GSK were worth $1,019,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. HHM Wealth Advisors LLC lifted its holdings in shares of GSK by 222.2% in the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of GSK in the first quarter valued at about $31,000. Richardson Financial Services Inc. lifted its holdings in shares of GSK by 127.9% in the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock valued at $33,000 after purchasing an additional 472 shares in the last quarter. Olde Wealth Management LLC purchased a new stake in shares of GSK in the first quarter valued at about $36,000. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in shares of GSK by 525.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock valued at $39,000 after buying an additional 852 shares during the period. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Trading Down 1.6%

GSK stock traded down $0.67 on Friday, hitting $40.81. 4,741,956 shares of the company were exchanged, compared to its average volume of 3,553,270. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $43.62. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The business's fifty day moving average is $38.74 and its two-hundred day moving average is $38.46. The stock has a market capitalization of $83.12 billion, a price-to-earnings ratio of 18.89, a price-to-earnings-growth ratio of 2.07 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. During the same quarter in the prior year, the business posted $0.43 earnings per share. GSK's revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, GSK presently has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.